- Home
- LENZ vs ESPR Comparison
LENZ vs ESPR Comparison
Compare LENZ & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LENZ | ESPR |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.0M | 898.5M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LENZ | ESPR |
|---|---|---|
| Price | $17.35 | $3.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $56.25 | $6.86 |
| AVG Volume (30 Days) | 1.1M | ★ 6.5M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,500,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | $204.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $15.70 | $0.69 |
| 52 Week High | $50.40 | $4.13 |
Technical Indicators
Market Signals| Indicator | LENZ | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 23.37 | 60.53 |
| Support Level | $15.70 | $3.72 |
| Resistance Level | $29.02 | $4.13 |
| Average True Range (ATR) | 2.37 | 0.26 |
| MACD | -0.91 | 0.00 |
| Stochastic Oscillator | 9.76 | 67.65 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.